Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Proxalutamide  COVID-19 treatment studies for Proxalutamide  C19 studies: Proxalutamide  Proxalutamide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 proxalutamide studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 84% 3 1,090 Improvement, Studies, Patients Relative Risk, 95% CI Mortality 84% 3 1,090 Ventilation 90% 3 1,090 Hospitalization 89% 2 445 Progression 78% 1 645 Recovery 72% 1 645 RCTs 84% 3 1,090 Peer-reviewed 80% 1 268 Early 73% 2 445 Late 84% 1 645 Proxalutamide for COVID-19 c19proxalutamide.com Dec 2, 2021 Favors proxalutamide Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Tau​2 = 0.00; I​2 = 0.0% Early treatment 73% 0.27 [0.03-2.39] 0/209 3/236 73% improvement Cadegiani (DB RCT) 84% 0.16 [0.11-0.24] death 35/317 197/328 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 84% 0.16 [0.11-0.24] 35/317 197/328 84% improvement All studies 84% 0.16 [0.12-0.22] 35/526 200/564 84% improvement 3 proxalutamide COVID-19 studies c19proxalutamide.com Dec 2, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 11.12 Effect extraction pre-specified Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] 0/75 1/102 Tau​2 = 0.00; I​2 = 0.0% Early treatment 73% 0.27 [0.03-2.39] 0/209 3/236 73% improvement Cadegiani (DB RCT) 84% 0.16 [0.11-0.24] 35/317 197/328 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 84% 0.16 [0.11-0.24] 35/317 197/328 84% improvement All studies 84% 0.16 [0.12-0.22] 35/526 200/564 84% improvement 3 proxalutamide COVID-19 mortality results c19proxalutamide.com Dec 2, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 11.12 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 97% 0.03 [0.00-0.47] 0/134 17/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 90% 0.10 [0.01-1.84] 0/75 5/102 Tau​2 = 0.00; I​2 = 0.0% Early treatment 95% 0.05 [0.01-0.40] 0/209 22/236 95% improvement Cadegiani (DB RCT) 89% 0.11 [0.04-0.31] 4/317 37/328 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 89% 0.11 [0.04-0.31] 4/317 37/328 89% improvement All studies 90% 0.10 [0.04-0.24] 4/526 59/564 90% improvement 3 proxalutamide COVID-19 mechanical ventilation results c19proxalutamide.com Dec 2, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 5.05 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 91% 0.09 [0.03-0.27] hosp. 3/134 35/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 86% 0.14 [0.03-0.60] hosp. 2/75 19/102 Tau​2 = 0.00; I​2 = 0.0% Early treatment 89% 0.11 [0.04-0.27] 5/209 54/236 89% improvement All studies 89% 0.11 [0.04-0.27] 5/209 54/236 89% improvement 2 proxalutamide COVID-19 hospitalization results c19proxalutamide.com Dec 2, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 4.86 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Tau​2 = 0.00; I​2 = 0.0% Early treatment 73% 0.27 [0.03-2.39] 0/209 3/236 73% improvement Cadegiani (DB RCT) 84% 0.16 [0.11-0.24] death 35/317 197/328 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 84% 0.16 [0.11-0.24] 35/317 197/328 84% improvement All studies 84% 0.16 [0.12-0.22] 35/526 200/564 84% improvement 3 proxalutamide COVID-19 serious outcomes c19proxalutamide.com Dec 2, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 11.12 Effect extraction pre-specified Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani (DB RCT) 72% 0.28 [0.21-0.37] no recov. 46/317 173/328 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 72% 0.28 [0.21-0.37] 46/317 173/328 72% improvement All studies 72% 0.28 [0.21-0.37] 46/317 173/328 72% improvement 1 proxalutamide COVID-19 recovery result c19proxalutamide.com Dec 2, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 8.84 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Tau​2 = 0.00; I​2 = 0.0% Early treatment 73% 0.27 [0.03-2.39] 0/209 3/236 73% improvement Cadegiani (DB RCT) 84% 0.16 [0.11-0.24] death 35/317 197/328 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 84% 0.16 [0.11-0.24] 35/317 197/328 84% improvement All studies 84% 0.16 [0.12-0.22] 35/526 200/564 84% improvement 3 proxalutamide COVID-19 Randomized Controlled Trials c19proxalutamide.com Dec 2, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 11.12 Effect extraction pre-specified Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] 0/75 1/102 Tau​2 = 0.00; I​2 = 0.0% Early treatment 73% 0.27 [0.03-2.39] 0/209 3/236 73% improvement Cadegiani (DB RCT) 84% 0.16 [0.11-0.24] 35/317 197/328 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 84% 0.16 [0.11-0.24] 35/317 197/328 84% improvement All studies 84% 0.16 [0.12-0.22] 35/526 200/564 84% improvement 3 proxalutamide COVID-19 RCT mortality results c19proxalutamide.com Dec 2, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 11.12 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 80% 0.20 [0.01-4.13] 0/134 2/134 80% improvement All studies 80% 0.20 [0.01-4.13] 0/134 2/134 80% improvement 1 proxalutamide COVID-19 peer reviewed trials c19proxalutamide.com Dec 2, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.04 Effect extraction pre-specified Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control McCoy (DB RCT) 97% 0.03 [0.00-0.47] ventilation 0/134 17/134 McCoy (DB RCT) 91% 0.09 [0.03-0.27] hosp. 3/134 35/134 Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Cadegiani (DB RCT) 90% 0.10 [0.01-1.84] ventilation 0/75 5/102 Cadegiani (DB RCT) 86% 0.14 [0.03-0.60] hosp. 2/75 19/102 Cadegiani (DB RCT) 84% 0.16 [0.11-0.24] death 35/317 197/328 Cadegiani (DB RCT) 89% 0.11 [0.04-0.31] ventilation 4/317 37/328 Cadegiani (DB RCT) 78% 0.22 [0.16-0.31] progression 36/317 168/328 Cadegiani (DB RCT) 72% 0.28 [0.21-0.37] no recov. 46/317 173/328 proxalutamide COVID-19 outcomes c19proxalutamide.com Dec 2, 2021 Favors proxalutamide Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit